David A. Siegel Galectin Therapeutics Inc Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
SELL
$2.24 - $2.87 $35,616 - $45,633
-15,900 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$2.53 - $3.64 $10,373 - $14,924
4,100 Added 34.75%
15,900 $42,000
Q2 2020

Aug 14, 2020
BUY
$1.66 - $3.15 $19,588 - $37,170
11,800 New
11,800 $36,000

Others Institutions Holding GALT

# of Institutions
90
Shares Held
9.57M
Call Options Held
1.16M
Put Options Held
1.98M
View Full List

About GALECTIN THERAPEUTICS INC

GALT Quotes by TradingView
  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $162M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email